Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Peripheral neuropathies; Rheumatic disorders
- Focus Adverse reactions
- 03 Oct 2018 Planned End Date changed from 16 May 2020 to 6 Mar 2019.
- 03 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 New trial record